6 / 33
Leighl– ASCO 2017
PD-L1 >50%--58%
N-27
3-y OS phase I KEYNOTE 001 Trial
|
|
6 / 33
6 / 33
Leighl– ASCO 2017
PD-L1 >50%--58%
N-27
3-y OS phase I KEYNOTE 001 Trial